Ipsen S.A. ADR (IPSEY) 15.4300 $IPSEY Ipsen's First Half

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ipsen S.A. ADR (IPSEY) 15.4300 $IPSEY

Ipsen's First Half 2016 Results
BusinessWire - Thu Jul 28, 12:01AM CDT
--Core Operating Income up 12.6% fueled by strong top-line growth

Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx(TM) (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
BusinessWire - Fri Jul 22, 9:26AM CDT
--Cabometyx(TM) (cabozantinib) is the first and only multi-kinase inhibitor with established clinical benefits demonstrated for all three key efficacy endpoints: overall survival (OS), progression-free survival (PFS) and objective response rate (ORR)
EXEL: 9.09 (+0.14)

Ipsen Announces the Acceptance by the European Medicines Agency of the Marketing Authorization Application for Telotristat Etiprate to Treat Carcinoid Syndrome Caused by Neuroendocrine Tumors, in Combination with Somatostatin Analogues
BusinessWire - Mon Jul 18, 11:01AM CDT
Regulatory News:

Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 9.09 (+0.14)

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 9.09 (+0.14)

Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma
BusinessWire - Mon May 23, 1:31PM CDT
Regulatory News:
EXEL: 9.09 (+0.14)

Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen's Paris-Saclay Campus
BusinessWire - Tue May 03, 12:39PM CDT
--Oncodesign teams are moving to Ipsen's private open innovation campus in Paris-Saclay
IPN: 29.34 (+0.29)

Ipsen's First Quarter 2016 Sales
BusinessWire - Thu Apr 28, 12:00AM CDT
--Specialty care sales up 9.7%(1), driven by the accelerated growth of Somatuline(R) in neuroendocrine tumors

Probi and Ipsen Sign Extensive Primary Care Distribution Agreement for Probiotic LP299V(R), Lactobacillus plantarum 299v
BusinessWire - Tue Apr 26, 1:45AM CDT
Regulatory News:

Ipsen is Pleased to Announce That Its Partner Exelixis Obtained FDA Approval of CABOMETYX(TM) (cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
BusinessWire - Mon Apr 25, 5:27PM CDT
--In February 2016, Exelixis and Ipsen entered into an exclusive licensing agreement to develop and commercialize cabozantinib in regions outside the United States, Canada and Japan
EXEL: 9.09 (+0.14)

Dassault Systemes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen's drug discovery
BusinessWire - Tue Apr 05, 12:00AM CDT
Regulatory News:

Exelixis Inc. Stock Was Throttled in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 06, 10:03AM CST
What: Shares of Exelixis , a biopharmaceutical company focused on the development of therapies to treat cancer, plunged 20% in February, based on data from S&P Global Market Intelligence . The two likely culprits appear to be market sentiment...
BMY: 74.83 (+0.17), EXEL: 9.09 (+0.14)

Ipsen report on voting rights and number of shares
M2 - Tue Feb 09, 6:57AM CST
Ipsen SA (Paris:IPN.PA) on Monday reported that as on 28 January 2016, the total number of shares in the company was 83,245,602.

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport(R) (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy
BusinessWire - Tue Jan 26, 1:14PM CST
Regulatory News:

Ipsen and Galderma Expand Current Distribution Agreement for Dysport(R) in Aesthetic Indications to Some Key Asia-Pacific Territories(1)
BusinessWire - Wed Jan 06, 12:00AM CST
Regulatory News:

Ipsen purchases 20,000 of own shares
M2 - Wed Dec 23, 5:21AM CST
Ipsen SA (Paris :IPN) on Tuesday reported that from 14 December 2015 to 18 December 2015, it has purchased a total of 20,000 of its own shares.
IPN: 29.34 (+0.29)

Ipsen Announces Its Corporate Agenda for 2016
BusinessWire - Thu Dec 17, 12:10PM CST
Regulatory News:

Ipsen reports on share purchase from 30 November to 4 December 2015
M2 - Tue Dec 08, 6:26AM CST
Ipsen SA (Paris:IPN) on Monday reported that during the period from 30 November 2015 to 4 December 2015, it purchased a total of 20,000 of its shares.
IPN: 29.34 (+0.29)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lawsuit Highlights Inaction in School Bus Tragedy

Updated Category News Views 3

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Updated Category News Views 6

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness

Updated Category News Views 6

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence

Updated Category News Views 3

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Continue Reading
Black Culture Icon: Plastic-Covered Couch Takes Stage

Updated Category News Views 3

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Continue Reading
SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Updated Category News Views 3

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Continue Reading
Class Action Alerts: M&A Under Scrutiny

Updated Category News Views 4

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Continue Reading
ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

Updated Category News Views 5

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris

Updated Category News Views 5

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Continue Reading
Blokees Unveils 90+ New Wonders at Shanghai Fest

Updated Category News Views 3

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring PBK Miner: Pioneering Sustainable Cloud Mining Solutions

Updated Category News Views 190

Discover PBK Miner’s Innovative Approach to Cloud Mining PBK Miner has emerged as a frontrunner in revolutionizing the cryptocurrency mining arena through its unique cloud mining contracts. This UK-based company has designed an innovative platform that enables users to effortlessly increase their income by accumulating cryptocurrency, making it easier than ever to build...

Continue Reading
Tesla Delivery Challenges Highlight Growing Market Competition

Updated Category News Views 439

Tesla's First Annual Delivery Decline Raises Industry Concerns Tesla (NASDAQ: TSLA), the well-known electric vehicle manufacturer, has faced its first-ever annual decline in vehicle deliveries. In the recent period, the company delivered 1.79 million vehicles, slightly lower than the 1.81 million units delivered the previous year. This downturn is unexpected for a brand...

Continue Reading
Therrel Baisden LLP: Celebrating a Century of Legal Excellence

Updated Category News Views 235

Therrel Baisden LLP Marks a Remarkable 100-Year Journey Therrel Baisden LLP, one of Florida’s esteemed boutique estate and trust law firms, is joyously commemorating its centenary. With a rich history of unmatched legal services, the firm has successfully catered to a diverse clientele, both domestically and internationally. A Legacy of Legal Excellence At the heart of...

Continue Reading
Nature's Path Elevates Leadership to Drive Growth Strategy

Updated Category News Views 153

Nature's Path Elevates Leadership for U.S. Growth Nature's Path Organic Foods, the prominent name in organic breakfast and snack foods in North America, has made a significant move by appointing Laura S. Chamberlain as their new Chief Customer Officer (CCO). This newly created role is set to enhance the company's commitment to growth within the U.S. market while nurturing...

Continue Reading
Iovance Biotherapeutics Set for Key Earnings Announcement

Updated Category News Views 232

Iovance Biotherapeutics Set for Key Earnings Announcement Iovance Biotherapeutics (NASDAQ: IOVA) is gearing up for its upcoming quarterly earnings report, and investors are keenly interested in what it has to offer. As anticipated, this announcement is set to unveil critical financial insights that could influence the company's future trajectory. Understanding Earnings...

Continue Reading